Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide in Non-Metastatic Androgen Independent Prostate Cancer
NCT00121238Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2005
- Primary completion
- Nov 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cilengitide in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Prostate Specific Antigen Response Rate up to 5 years. Started Jan 2005; status: completed.
02
Drugs
cilengitide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00121238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121238.